Published by Josh White on 23rd October 2025
(Sharecast News) - Shield Therapeutics reported its strongest quarterly performance to date on Thursday, with third-quarter Accrufer prescriptions rising about 15% from the previous quarter and revenues reaching a new high, keeping the company on track to become cash flow positive by year-end.